Testicular ultrasonographic features predict future risk for bilateral testicular germ cell tumour: A long-term single centre follow-up study.
bilateral testicular tumours
microlithiasis
mixed germ cell tumours
seminoma
testicular ultrasound
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
revised:
01
07
2024
received:
12
03
2024
accepted:
05
07
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
30
7
2024
Statut:
aheadofprint
Résumé
Bilateral testicular germ cell tumours (B-GCT) are rare, with an incidence of 2-5%, and can be classified as synchronous (sB-GCT) or metachronous (mB-GCT). Our study aimed to identify clinical, biochemical, and radiological risk factors for mB-GCT in a cohort of patients with GCT at a single tertiary referral centre. This retrospective case-control study included patients with GCT referred to Policlinico Umberto I-Sapienza University of Rome, from 2005 to 2023. We evaluated clinical history, testicular ultrasound features, hormone levels, semen analysis, histological characteristics, staging, and treatments. mB-GCTs were compared with unilateral GCT patients with a follow-up longer than the median time-to-onset of the second tumour. Of 319 patients, 52 experienced B-GCT, with a median time-to-onset of the second tumour of 62 months (range: 8-229). The mB-GCT group showed higher gonadotropin levels (FSH 13.6mUI/mL vs. 7.4mUI/mL, p < 0.001; LH 6.6mUI/mL vs. 3.9mUI/mL, p = 0.004), lower sperm concentration (27 × 10 Histological features of the first tumour or its treatment do not influence the onset of a second tumour. However, low residual testis volume, inhomogeneous echotexture, and microlithiasis significantly increase this risk. A comprehensive evaluation of the residual testis at baseline is essential for developing a personalised surveillance programme in GCT survivors, with regular ultrasound follow-up recommended beyond the conventional 5-year limit.
Sections du résumé
BACKGROUND
BACKGROUND
Bilateral testicular germ cell tumours (B-GCT) are rare, with an incidence of 2-5%, and can be classified as synchronous (sB-GCT) or metachronous (mB-GCT). Our study aimed to identify clinical, biochemical, and radiological risk factors for mB-GCT in a cohort of patients with GCT at a single tertiary referral centre.
METHODS
METHODS
This retrospective case-control study included patients with GCT referred to Policlinico Umberto I-Sapienza University of Rome, from 2005 to 2023. We evaluated clinical history, testicular ultrasound features, hormone levels, semen analysis, histological characteristics, staging, and treatments. mB-GCTs were compared with unilateral GCT patients with a follow-up longer than the median time-to-onset of the second tumour.
RESULTS
RESULTS
Of 319 patients, 52 experienced B-GCT, with a median time-to-onset of the second tumour of 62 months (range: 8-229). The mB-GCT group showed higher gonadotropin levels (FSH 13.6mUI/mL vs. 7.4mUI/mL, p < 0.001; LH 6.6mUI/mL vs. 3.9mUI/mL, p = 0.004), lower sperm concentration (27 × 10
CONCLUSIONS
CONCLUSIONS
Histological features of the first tumour or its treatment do not influence the onset of a second tumour. However, low residual testis volume, inhomogeneous echotexture, and microlithiasis significantly increase this risk. A comprehensive evaluation of the residual testis at baseline is essential for developing a personalised surveillance programme in GCT survivors, with regular ultrasound follow-up recommended beyond the conventional 5-year limit.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Ministry of Health: PRecisiOn MEdicine to Target Frailty of Endocrine-metabolic Origin (PROMETEO) project
ID : NET-2018-12365454
Organisme : European Union Next Generation EU through the Italian Ministry of University and Research: PNRR M4C2-I1.3 Project PE_00000019 "HEALITALIA"
ID : CUPB53C22004000006
Informations de copyright
© 2024 The Author(s). Andrology published by John Wiley & Sons Ltd on behalf of American Society of Andrology and European Academy of Andrology.
Références
Gurney JK, Florio AA, Znaor A, et al. International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries. Eur Urol. 2019;76(5):615‐623.
Znaor A, Skakkebaek NE, Rajpert‐De Meyts E, et al. Global patterns in testicular cancer incidence and mortality in 2020. Int J Cancer. 2022;151(5):692‐698.
Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs‐Part A: renal, penile, and testicular tumours. Eur Urol. 2022;82(5):458‐468.
Rajpert‐De Meyts E, McGlynn KA, Okamoto K, Jewett MAS, Bokemeyer C. Testicular germ cell tumours. Lancet. 2016;387(10029):1762‐1774.
de Zequi SC, da Costa WH, Santana TBM, Favaretto RL, Sacomani CAR, Guimaraes GC. Bilateral testicular germ cell tumours: a systematic review. BJU Int. 2012;110(8):1102‐1109.
Rajpert‐De Meyts E, Aksglaede L, Bandak M, Toppari J, Jørgensen N. Testicular cancer: pathogenesis, diagnosis and management with focus on endocrine aspects. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, eds. Endotext. MDText.com, Inc.; 2023.
Nery F, Valadares D, Marques F. Metachronous testicular germ‐cell tumors: the importance of a long‐term follow‐up. World J Oncol. 2010;1(3):145‐147.
Sun BL, Pearl R, Sharifi R, Guzman G. Metachronous bilateral testicular seminoma developing after an interval of 31 years: case report and review of the literature. Int J Surg Pathol. 2015;23(2):156‐160.
Dieckmann KP, Anheuser P, Sattler F, Von Kügelgen T, Matthies C, Ruf C. Sequential bilateral testicular tumours presenting with intervals of 20 years and more. BMC Urol. 2013;13:71.
Tenuta M, Sesti F, Bonaventura I, et al. Use of contrast enhanced ultrasound in testicular diseases: a comprehensive review. Andrology. 2021;9(5):1369‐1382.
Pozza C, Kanakis G, Carlomagno F, et al. Testicular ultrasound score: a new proposal for a scoring system to predict testicular function. Andrology. 2020;8(5):1051‐1063.
Kliesch S, Schmidt S, Wilborn D, et al. Management of germ cell tumours of the testis in adult patients. german clinical practice guideline part i: epidemiology, classification, diagnosis, prognosis, fertility preservation, and treatment recommendations for localized stages. Urol Int. 2021;105(3‐4):169‐180.
Banna GL, Nicolai N, Palmieri G, et al. Recommendations for surveillance and follow‐up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ Cell Cancer Group and the Associazione Italiana di Oncologia Medica. Crit Rev Oncol Hematol. 2019;137:154‐164.
Murez T, Fléchon A, Branger N, et al. French AFU Cancer Committee Guidelines—Update 2022–2024: testicular germ cell cancer. Prog Urol. 2022;32(15):1066‐1101.
Patrikidou A, Cazzaniga W, Berney D, et al. European Association of Urology Guidelines on Testicular Cancer: 2023 update. Eur Urol. 2023;84(3):289‐301.
Oldenburg J, Berney DM, Bokemeyer C, et al. Testicular seminoma and non‐seminoma: ESMO‐EURACAN Clinical Practice Guideline for diagnosis, treatment and follow‐up. Ann Oncol. 2022;33(4):362‐375.
Pozza C, Sesti F, Tenuta M, et al. Testicular dysfunction in 47, XXY boys: when it all begins. a semilongitudinal study. J Clin Endocrinol Metab. 2023;108(10):2486‐2499.
Carlomagno F, Pozza C, Tenuta M, et al. Testicular microvascular flow is altered in Klinefelter syndrome and predicts circulating testosterone. J Clin Endocrinol Metab. 2022;107(1):e236‐e245.
World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen.; 2010.
World Health Organisation. WHO Laboratory Manual for the Examination of Human Semen and Sperm‐Cervical Mucus Interaction. Cambridge University Press; 1999.
Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010;16(3):231‐245.
Lotti F, Frizza F, Balercia G, et al. The European Academy of Andrology (EAA) ultrasound study on healthy, fertile men: an overview on male genital tract ultrasound reference ranges. Andrology. 2022;10(2):118‐132. Suppl.
Iczkowski KA. Germ cell neoplasms of the testis: update for 2022. Semin Diagn Pathol. 2023;40(1):2‐21.
Kopp RP, Chevinsky M, Bernstein M, et al. Bilateral testicular germ cell tumors in the era of multimodal therapy. Urology. 2017;103:154‐160.
Klatte T, de Martino M, Arensmeier K, Reiher F, Allhoff EP, Klatte D. Management and outcome of bilateral testicular germ cell tumors: a 25‐year single center experience. Int J Urol. 2008;15(9):821‐826.
Maroto P, García Del Muro X, Valverde C, et al. Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer. Urol Oncol. 2021;39(2):135.e17‐e135.e23.
Fosså SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population‐based study of 29,515 U.S. men. J Natl Cancer Inst. 2005;97(14):1056‐1066.
Mrinakova B, Trebaticky B, Kajo K, et al. Bilateral testicular germ cell tumors ‐ 50 years experience. Bratisl Lek Listy. 2021;122(7):449‐453.
Pozza C, Pofi R, Tenuta M, et al. Clinical presentation, management and follow‐up of 83 patients with Leydig cell tumors of the testis: a prospective case‐cohort study. Hum Reprod. 2019;34(8):1389‐1403.
Pozza C, Tenuta M, Sesti F, et al. Multiparametric ultrasound for diagnosing testicular lesions: everything you need to know in daily clinical practice. Cancers. 2023;15(22). doi:10.3390/cancers15225332
Theodore C, Terrier‐Lacombe MJ, Laplanche A, et al. Bilateral germ‐cell tumours: 22‐year experience at the Institut Gustave Roussy. Br J Cancer. 2004;90(1):55‐59.
Watson RA, Morgan RD, Joseph J, et al. Bilateral testicular germ cell tumors: a case‐series from a UK‐based tertiary referral center over 19 years. Clin Genitourin Cancer. 2018;16(3):e513‐e516.
Ondruš D, Ondrušová M, Št'astná V. Bilateral germ‐cell testicular cancer—long‐term experience. Klin Onkol. 2013;26(6):421‐424.
Wanderås EH, Fosså SD, Tretli S. Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients. Eur J Cancer. 1997;33(2):244‐252.
Osterlind A, Berthelsen JG, Abildgaard N, et al. Risk of bilateral testicular germ cell cancer in Denmark: 1960–1984. J Natl Cancer Inst. 1991;83(19):1391‐1395.
Blok JM, Groot HJ, Huele EH, et al. Dose‐dependent effect of platinum‐based chemotherapy on the risk of metachronous contralateral testicular cancer. J Clin Oncol. 2021;39(4):319‐327.
Che M, Tamboli P, Ro JY, et al. Bilateral testicular germ cell tumors: twenty‐year experience at M. D. Anderson Cancer Center. Cancer. 2002;95(6):1228‐1233.
Hemminki K, Liu H, Sundquist J. Second cancers after testicular cancer diagnosed after 1980 in Sweden. Ann Oncol. 2010;21(7):1546‐1551.
Park DS, Prow DM, Amato RJ, Ro JY, Logothetis CJ. Clinical characteristics of metachronous bilateral testicular tumors in the chemotherapeutic era. Yonsei Med J. 1999;40(2):137‐143.
Hellesnes R, Myklebust TÅ, Bremnes RM, et al. Metachronous contralateral testicular cancer in the cisplatin era: a population‐based cohort study. J Clin Oncol. 2021;39(4):308‐318.
Andreassen KE, Grotmol T, Cvancarova MS, Johannesen TB, Fosså SD. Risk of metachronous contralateral testicular germ cell tumors: a population‐based study of 7,102 Norwegian patients (1953‐2007). Int J Cancer. 2011;129(12):2867‐2874.
Ruf CG, Khalili‐Harbi N, Sachs S, et al. The search for biomarkers of metastatic seminoma. J Urol. 2013;190(3):1046‐1051.
Aparicio J, Maroto P, García Del Muro X, et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk‐adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol. 2014;25(11):2173‐2178.
Mortensen MS, Lauritsen J, Kier MGG, et al. Late relapses in stage I testicular cancer patients on surveillance. Eur Urol. 2016;70(2):365‐371.
Tandstad T, Solberg A, Håkansson U, et al. Bilateral testicular germ cell tumors in patients treated for clinical stage I non‐seminoma within two risk‐adapted SWENOTECA protocols. Acta Oncol. 2015;54(4):493‐499.
Kleinschmidt K, Dieckmann KP, Georgiew A, Loy V, Weissbach L. Chemotherapy is of limited efficacy in the control of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell cancer. Oncology. 2009;77(1):33‐39.
Bottomley D, Fisher C, Hendry WF, Horwich A. Persistent carcinoma in situ of the testis after chemotherapy for advanced testicular germ cell tumours. Br J Urol. 1990;66(4):420‐424.
van Leeuwen FE, Stiggelbout AM, van den Belt‐Dusebout AW, et al. Second cancer risk following testicular cancer: a follow‐up study of 1,909 patients. J Clin Oncol. 1993;11(3):415‐424.
Géczi L, Gomez F, Bak M, Bodrogi I. The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary. J Cancer Res Clin Oncol. 2003;129(5):309‐315.
Chung P, Warde P. Stage I seminoma: adjuvant treatment is effective but is it necessary? J Natl Cancer Inst. 2011;103(3):194‐196.
Oliver RTD, Mead GM, Rustin GJS, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011;29(8):957‐962.
Dieckmann KP, Wilken S, Loy V, et al. Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum‐based chemotherapy: a survey of the German Testicular Cancer Study Group. Ann Oncol. 2013;24(5):1332‐1337.
van Basten JP, Hoekstra HJ, van Driel MF, Sleijfer DT, Droste JH, Schraffordt Koops H. Cisplatin‐based chemotherapy changes the incidence of bilateral testicular cancer. Ann Surg Oncol. 1997;4(4):342‐348.
Schaapveld M, van den Belt‐Dusebout AW, Gietema JA, et al. Risk and prognostic significance of metachronous contralateral testicular germ cell tumours. Br J Cancer. 2012;107(9):1637‐1643.
Brabrand S, Fosså SD, Cvancarova M, Axcrona U, Lehne G. Probability of metachronous testicular cancer in patients with biopsy‐proven intratubular germ cell neoplasia depends on first‐time treatment of germ cell cancer. J Clin Oncol. 2012;30(32):4004‐4010.
Gupta M, Cheaib JG, Patel HD, et al. Diagnosis and management of intratubular germ cell neoplasia in situ: a systematic review. J Urol. 2020;204(1):33‐41.
Skakkebaek NE, Rajpert‐De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod. 2001;16(5):972‐978.
Skakkebaek NE, Rajpert‐De Meyts E, Buck Louis GM, et al. Male reproductive disorders and fertility trends: influences of environment and genetic susceptibility. Physiol Rev. 2016;96(1):55‐97.
Kliesch S, Bergmann M, Hertle L, Nieschlag E, Behre HM. Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies. Hum Reprod. 1997;12(12):2830‐2835.
Dieckmann KP, Loy V. Paternity in a patient with testicular seminoma and contralateral testicular intraepithelial neoplasia. Int J Androl. 1993;16(2):143‐146.
Fordham MV, Mason MD, Blackmore C, Hendry WF, Horwich A. Management of the contralateral testis in patients with testicular germ cell cancer. Br J Urol. 1990;65(3):290‐293.
Wanderas EH, Fosså SD, Heilo A, Stenwig AE, Norman N. Serum follicle stimulating hormone–predictor of cancer in the remaining testis in patients with unilateral testicular cancer. Br J Urol. 1990;66(3):315‐317.
Jacobsen KD, Fosså SD, Bjøro TP, Aass N, Heilo A, Stenwig AE. Gonadal function and fertility in patients with bilateral testicular germ cell malignancy. Eur Urol. 2002;42(3):238.
Harland SJ, Cook PA, Fossa SD, et al. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol. 1998;160(4):1353‐1357.
Rud CN, Daugaard G, Rajpert‐De Meyts E, Skakkebæk NE, Petersen JH, Jørgensen N. Sperm concentration, testicular volume and age predict risk of carcinoma in situ in contralateral testis of men with testicular germ cell cancer. J Urol. 2013;190(6):2074‐2080.
Dieckmann KP, Loy V. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol. 1996;14(12):3126‐3132.
Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two‐site biopsies are more sensitive than a single random biopsy. Eur Urol. 2007;51(1):175‐183. discussion 183–185.
Tan IB, Ang KK, Ching BC, Mohan C, Toh CK, Tan MH. Testicular microlithiasis predicts concurrent testicular germ cell tumors and intratubular germ cell neoplasia of unclassified type in adults: a meta‐analysis and systematic review. Cancer. 2010;116(19):4520‐4532.
Leblanc L, Lagrange F, Lecoanet P, Marçon B, Eschwege P, Hubert J. Testicular microlithiasis and testicular tumor: a review of the literature. Basic Clin Androl. 2018;28:8.
D'Andrea S, Martorella A, Castellini C, et al. Clinical and seminal parameters associated with testicular microlithiasis and its severity in males from infertile couples. Hum Reprod. 2021;36(4):891‐898.
Aoun F, Slaoui A, Naoum E, et al. Testicular microlithiasis: systematic review and clinical guidelines. Prog Urol. 2019;29(10):465‐473.
Bach AM, Hann LE, Shi W, et al. Is there an increased incidence of contralateral testicular cancer in patients with intratesticular microlithiasis? AJR Am J Roentgenol. 2003;180(2):497‐500.
Dieckmann KP, Heinemann V, Frey U, Pichlmeier U. German Testicular Cancer Study Group. How harmful is contralateral testicular biopsy?–An analysis of serial imaging studies and a prospective evaluation of surgical complications. Eur Urol. 2005;48(4):662‐672.
Dieckmann KP, Loy V. False‐negative biopsies for the diagnosis of testicular intraepithelial neoplasia (TIN)–an update. Eur Urol. 2003;43(5):516‐521.
Rajpert‐De Meyts E, Jørgensen N, Petersen JH, et al. Optimized detection of germ cell neoplasia in situ in contralateral biopsy reduces the risk of second testis cancer. BJU Int. 2022;130(5):646‐654.
Kier MGG, Lauritsen J, Almstrup K, et al. Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population‐based study. Ann Oncol. 2015;26(4):737‐742.
Mortensen MS, Gundgaard MG, Daugaard G. Treatment options for carcinoma in situ testis. Int J Androl. 2011;34(4):e32‐e36. Pt 2.
Dieckmann KP, Tribius S, Angerer M, et al. Testicular germ cell tumour arising 15 years after radiotherapy with 18 Gy for germ cell neoplasia in situ. Strahlenther Onkol. 2023;199(3):322‐326.
Heidenreich A. Contralateral testicular biopsy in testis cancer: current concepts and controversies. BJU Int. 2009;104(9):1346‐1350. Pt B.
Isidori AM, Dogra VS, Sidhu PS. Imaging andrology of the future: where functional imaging embraces the clinic. Andrology. 2021;9(5):1287‐1289.
Sidhu PS, Cantisani V, Dietrich CF, et al. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast‐Enhanced Ultrasound (CEUS) in non‐Hepatic applications: update 2017 (long version). Ultraschall Med. 2018;39(2):e2‐e44.